Home > Insider Trading > Filing (0001246360-13-002419)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
911326	Synageva Biopharma Corp	GEVA	Biological Products, (No Disgnostic Substances) (2836)	561808663

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1532218	K Sanj Patel	128 Spring Street, Suite 520 Lexington MA 02421	President & Ceo	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2013-04-05	9,910	$0.95	10,941	No	4	M	Direct
Common Stock	Disposition	2013-04-05	9,910	$50.11	1,031	No	4	S	Direct
Common Stock	Acquisiton	2013-04-08	21,695	$0.95	22,726	No	4	M	Direct
Common Stock	Disposition	2013-04-08	21,695	$49.49	1,031	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2013-04-05	9,910	$0.00	9,910	$0.95
Common Stock	Stock Option (Right to Buy)	Disposition	2013-04-08	21,695	$0.00	21,695	$0.95

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
63,191		2019-12-15	No	4	M	Direct
41,496		2019-12-15	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	286	Indirect	Held by Abbey Road Investment Group

Footnotes

The stock option exercise and sale of shares of common stock ("Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 5, 2012.
The stock option granted the reporting person an option to purchase 117,220 Shares. 25% of such Shares vested and became exercisable on 09/25/2010, and 1/36 of the remainder of such Shares vest and become exercisable monthly thereafter.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $49.91 to $50.88. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $49.30 to $50.05. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.